Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

Elevance Health stock faces a higher earnings and margin test

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Elevance Health raised its adjusted 2026 EPS outlook to at least $29.00 following a strong third-quarter operating performance.

πŸ’° Third-quarter operating revenue reached $50.4 billion, up 0.7% from the prior-year period, driven by improved operations.

πŸ“‰ Medical membership declined by approximately 487,000 year-over-year to roughly 44.9 million despite higher Health Benefits revenue.

πŸ’΅ Adjusted diluted earnings per share for the third quarter came to $6.99, supported by a net non-operating benefit of $1.85.

πŸš€ Management reiterated an expectation for at least 12% adjusted EPS growth in 2027 with a higher baseline set.

πŸ“Š Zacks Research lifted its 2026 EPS forecast to $29.02, though the estimate remains below the analyst consensus of $29.18.

πŸ₯ The benefit expense ratio improved to 90.6% in the third quarter as the company made targeted investments.

πŸ“‰ Medicaid margins are expected to reach a trough in 2026 before improving in 2027 with a higher long-term target.

βš–οΈ Investors will focus on medical cost trends and evidence that pricing is catching up with care costs.

πŸ’Ή The stock traded at 382.25 euros as of November 7, 2026, facing a test to prove margin improvements can persist.

Bullish Signals
  • Elevance Health raised its adjusted 2026 EPS outlook to at least $29.00 after third-quarter operating performance exceeded expectations.
  • The company reported third-quarter operating revenue of $50.4 billion, a 0.7% increase year-over-year, demonstrating resilient top-line growth.
  • Adjusted diluted earnings per share reached $6.99 in the third quarter, supported by improved operating performance and a $1.85 non-operating benefit.
  • Management set a higher earnings baseline of at least $26.75 for 2026 and reaffirmed its target for at least 12% adjusted EPS growth in 2027.
  • Zacks Research increased its full-year 2026 EPS forecast to $29.02, signaling analyst confidence in the company's revised guidance.
  • The benefit expense ratio improved to 90.6% in the third quarter, indicating better cost management despite targeted investments.
Risk Factors
  • Medical membership fell by approximately 487,000 year-over-year to roughly 44.9 million, raising concerns about member retention or acquisition challenges.
  • Segment operating gain declined in the third quarter as the company made targeted investments, potentially impacting short-term profitability.
  • Zacks Research's revised EPS forecast of $29.02 remains below the broader analyst consensus of $29.18, suggesting some analysts remain cautious.
Full Analysis
Elevance Health has raised its adjusted earnings outlook for 2026 following a stronger third-quarter operating performance. The company reported third-quarter operating revenue of $50.4 billion, representing a 0.7% increase year-over-year, with adjusted diluted earnings per share reaching $6.99. This improvement was supported by enhanced operating metrics and a net non-operating benefit of $1.85 per share. Management has updated its forward guidance, raising the 2026 adjusted diluted EPS outlook to at least $29.00 and increasing the operating cash flow forecast to at least $6.5 billion. Additionally, Elevance Health established a higher earnings baseline of at least $26.75 for 2026 and reiterated its expectation for at least 12% adjusted EPS growth in 2027. Analyst Zacks Research lifted its full-year 2026 EPS forecast to $29.02, though this remains slightly below the broader analyst consensus of $29.18. While the insurer successfully improved its benefit expense ratio to 90.6% in the third quarter, it faced a decline in medical membership of approximately 487,000 members year-over-year as it made targeted investments. Investors are closely monitoring Medicaid and Medicare Advantage segments, which remain central to the company's investment case. Elevance Health expects its Medicaid margin to bottom out in 2026 before improving in 2027, with a longer-term target range set higher. The market will focus on whether pricing power can effectively catch up with rising care costs and sustain membership growth.